Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:ATGNASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATGAtlanta GoldC$0.03+∞C$0.03C$0.03▼C$0.06C$2.28MN/A55,868 shs3,200 shsSOPHSOPHiA GENETICS$2.93-2.0%$3.05$2.58▼$6.28$195.33M1.0362,572 shs15,281 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATGAtlanta Gold0.00%0.00%0.00%0.00%0.00%SOPHSOPHiA GENETICS-2.01%-3.30%-0.34%-19.73%-36.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATGAtlanta GoldN/AN/AN/AN/AN/AN/AN/AN/ASOPHSOPHiA GENETICS2.0768 of 5 stars3.45.00.00.01.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATGAtlanta Gold 0.00N/AN/AN/ASOPHSOPHiA GENETICS 2.75Moderate Buy$6.80132.08% UpsideCurrent Analyst Ratings BreakdownLatest ATG, SOPH, PRSM, and KAPE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/6/2025SOPHSOPHiA GENETICSBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.00(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATGAtlanta GoldN/AN/AN/AN/AC$0.39 per shareN/ASOPHSOPHiA GENETICS$67.17M2.91N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATGAtlanta GoldN/A-C$0.02N/A∞N/AN/AN/AN/AN/ASOPHSOPHiA GENETICS-$78.98M-$1.00N/AN/AN/A-110.71%-55.06%-38.33%N/ALatest ATG, SOPH, PRSM, and KAPE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025SOPHSOPHiA GENETICS-$0.21-$0.26-$0.05-$0.26$16.76 million$17.78 million3/4/2025Q4 2024SOPHSOPHiA GENETICS-$0.23-$0.23N/A-$0.23$17.71 million$17.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATGAtlanta GoldN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATGAtlanta Gold31.940.00N/ASOPHSOPHiA GENETICS0.123.803.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATGAtlanta GoldN/ASOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipATGAtlanta GoldN/ASOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATGAtlanta GoldN/A76.15 millionN/ANot OptionableSOPHSOPHiA GENETICS52066.69 million62.19 millionNot OptionableATG, SOPH, PRSM, and KAPE HeadlinesRecent News About These CompaniesThe Sophia Case: When Parenthood Isn’t Just About GeneticsMay 10 at 9:22 PM | blogs.timesofisrael.comSOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call TranscriptMay 10 at 4:01 AM | seekingalpha.comSOPHiA GENETICS (NASDAQ:SOPH) Releases Earnings Results, Misses Expectations By $0.05 EPSMay 8 at 10:11 AM | marketbeat.comSophia Genetics SA (SOPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Improved ...May 7 at 7:44 AM | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comSOPHiA GENETICS Reports First Quarter 2025 ResultsMay 6, 2025 | prnewswire.comSOPHiA GENETICS (SOPH) Projected to Post Earnings on TuesdayMay 1, 2025 | marketbeat.comSOPHiA GENETICS expands AstraZeneca liquid biopsy testApril 30, 2025 | investing.comSOPHiA GENETICS Expands AstraZeneca Partnership to Advance Liquid Biopsy WorldwideApril 29, 2025 | msn.comSOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACRApril 28, 2025 | prnewswire.comSOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025April 22, 2025 | prnewswire.comSophia Genetics, Precision for Medicine enter strategic partnershipApril 9, 2025 | markets.businessinsider.comPrecision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy CapabilitiesApril 8, 2025 | prnewswire.comSOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock?March 21, 2025 | zacks.comMorgan Stanley Keeps Their Hold Rating on SOPHiA GENETICS (SOPH)March 20, 2025 | markets.businessinsider.comSOPHiA GENETICS (SOPH) Gets a Buy from BTIGMarch 18, 2025 | markets.businessinsider.comSOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTCMarch 18, 2025 | prnewswire.comSOPHiA GENETICS (SOPH) Receives a Buy from BTIGMarch 12, 2025 | markets.businessinsider.comBaby Sophia from embryo swap will stay with birth parents court rules on appealMarch 11, 2025 | msn.comDistrict Court rules to keep IVF child with birth mother following embryo mix-upMarch 10, 2025 | msn.comCourt overturns ruling that ordered toddler returned to genetic parents following embryo mix-upMarch 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATG, SOPH, PRSM, and KAPE Company DescriptionsAtlanta Gold CVE:ATGC$0.03 +0.03 (+∞) As of 05/1/2019Atlanta Gold Inc. operates as a junior gold exploration and development company in the United States. Its principal property is the Atlanta gold property that covers an area of 2,159 acres located in Idaho. The company was formerly known as Twin Mining Corporation and changed its name to Atlanta Gold Inc. in March 2007. Atlanta Gold Inc. was founded in 1985 and is headquartered in Toronto, Canada.SOPHiA GENETICS NASDAQ:SOPH$2.93 -0.06 (-2.01%) As of 05/9/2025 03:59 PM EasternSOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
